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Ascertaining the adverse effects (AEs) of a antiepileptic drug (AED) can be a very tricky business. It seems like it should be easy: just give it to a bunch of people and see what happens. That works for some AEs, but for others it can be quite problematic. For example, some AEs are vague and hard to define (e.g., fatigue), and some can be confounded by their relationship to the underlying disease (e.g., cognitive impairment, depressed mood). The clearest way to establish causation is with a randomized trial, which can sometimes address these issues. But there are other side effects that are relatively rare (e.g., aplastic anemia) or that only occur over a protracted period of time (e.g., osteoporosis). For these latter types of AEs, no randomized trial could be large enough or long enough to establish causation, thereby requiring Plan B.
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inducing AED use (2, 3) . Unfortunately, the results have been conflicting, which illustrates the challenge of this approach.
Yet another alternative, and one that is particularly salient for slowly developing AEs, is to examine surrogate markers for a given pathologic condition. This approach has been used commonly in the area of bone effects, demonstrating, for example, that there is significantly greater decline in bone mass over time with the use of phenytoin (PHT) (4, 5) . Bone density is such a strong surrogate marker for fracture risk that this is tantamount to showing that PHT increases the incidence of fractures.
Vascular effects of AEDs are another area in which the latter approach has been employed. The extensive research into surrogate markers for coronary artery disease provides many opportunities to examine the potential effects of AEDs on vascular health. Among the most well-established markers for vascular disease is serum cholesterol, a measure of such long standing that it has seeped deeply into lay consciousness. This makes it quite easy for patients-and physicians-to understand the implications of the finding that enzyme-inducing AEDs raise cholesterol by an average of 26 mg/dL, to say nothing of the other vascular risk markers that are likewise elevated by enzyme-inducing AED use (6) . Now the next step in the pathologic process of vascular disease has been examined by Chuang et al,. with striking results. This group assessed another surrogate marker: the combined thickness of the intimal and medial layers of the carotid artery (CIMT). CIMT is, in essence, a measure of the amount of atherosclerotic plaque on the carotid wall, so it is not surprising to find that it is a strong marker for risk of stroke. But it is also a strong and well-established surrogate marker for myocardial infarction risk (7) , presumably because the state of the carotid reflects the state of the rest of the body's vasculature as well.
A previous study by these authors, along with two other studies from different groups, demonstrated that CIMT is elevated in drug-treated epilepsy patients, though there was no separation of individual drugs' effects (8) (9) (10) . This time, the authors assessed CIMT in epilepsy patients treated with one of four drugs-carbamazepine (CBZ), phenytoin (PHT), valproate (VPA), or lamotrigine (LTG)-in monotherapy. They verified previous findings that serum lipids, homocysteine, and C-reactive protein were all significantly elevated in patients taking the former two enzyme-inducing drugs (6, 11) . They also demonstrated, for the first time, that CIMT was significantly elevated in patients taking one of the three older drugs, but not those taking LTG, relative to controls. Even more striking was the finding that duration of therapy with CBZ, PHT, or VPA-but not LTG-was significantly correlated with CIMT, after correction for age and sex.
Thus, the picture this paints is one of drugs that gradually and steadily increase the amount of atherosclerotic plaque over years of use-exactly what one would expect from the serologic data showing increases in lipids and other vascular risk markers. The particular value of this study is that its results, using a surrogate marker separate from those measured in blood, point in a concordant fashion toward the notion that the enzyme-inducing AEDs may well be responsible for accelerated atherogenesis. And, while surrogate markers cannot fully replace direct examination of the disease state, when multiple lines of evidence converge, the underlying concept becomes that much harder to dismiss.
If there's a wrinkle here, it's with the results vis-à-vis VPA, which has been shown in a number of studies to reduce serum lipids (12, 13) . Despite this, the Chuang et al. study shows increased CIMT in patients taking the drug, leaving us with a situation in which two reliable surrogate markers point in different directions. Epidemiologic study of vascular risk has suggested that risk of myocardial infarction and vascular death may be lower in VPA-treated patients (14) , implying that the CIMT findings of the present study may be off-base with regard to VPA-treated patients.
The latter point underscores the fact that even wellvalidated surrogate markers can sometimes lead us astray. The presumptive atherogenic effects of enzyme-inducing AEDs will be more convincingly proved when there is good epidemiologic evidence that the drugs are associated with clinical disease, and very little such data exist at present (15) . Nonetheless, the surrogate marker data in this article and in the others discussed here should be cause for concern among all who prescribe these drugs. At present, the only prudent course of action is to perform cardiac screening of some kind-serologic or imaging-in all patients who take enzyme-inducing AEDs. And if doing so unduly increases the cost, worry, and hassle of using these agents, then perhaps it's time to think twice before prescribing them in the first place.
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